Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Bristol-Myers Squibb Company Ce's quarterly P/E stands at 0.0x, down 61.6% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 18.7% YoY to 1.8x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.02 | 0.01 | 0.01 | 0.01 | 0.35 | 0.02 | 0.01 | — | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| — | -61.6% | -20.9% | — | +1241.8% | -21.7% | -55.5% | — | -16.7% | -45.3% | — | — | — | |
| P/S Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| — | -32.4% | -39.1% | -3.0% | -49.3% | -54.2% | -66.9% | -60.1% | -27.4% | -33.3% | — | — | — | |
| P/B Ratio | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -35.8% | -40.2% | -13.2% | -1.9% | -16.0% | -32.5% | -19.5% | -23.0% | -26.6% | — | — | — | |
| P/FCF | — | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.04 | 0.02 | 0.02 |
| — | -39.0% | -64.5% | +37.8% | -47.3% | -58.4% | -71.6% | -55.9% | -44.9% | -49.1% | — | — | — | |
| EV / EBITDA | — | 1.82 | 1.86 | 2.22 | 2.33 | 2.23 | 2.79 | 2.98 | 1.73 | 1.20 | 1.79 | 1.57 | 1.89 |
| — | -18.7% | -33.1% | -25.3% | +34.7% | +86.4% | +55.9% | +89.3% | -8.5% | -30.9% | — | — | — | |
| EV / EBIT | — | 2.46 | 4.25 | 2.92 | 15.26 | 5.00 | 6.61 | — | 3.79 | 3.30 | 3.62 | 2.50 | 3.70 |
| — | -50.8% | -35.8% | — | +302.4% | +51.3% | +82.7% | — | +2.5% | +2.0% | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Bristol-Myers Squibb Company Ce's operating margin was 31.5% in Q3 2025, down 2.1 pp QoQ and up 12.2 pp YoY. The trailing four-quarter average of 29.2% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 18.6% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.8% | 66.0% | 65.8% | 65.5% | 60.2% | 55.6% | 73.2% | 75.3% | 76.1% | 77.1% | 74.4% | 77.4% | 77.3% |
| — | +18.6% | -10.2% | -13.0% | -20.9% | -27.9% | -1.6% | -2.7% | -1.5% | -2.4% | -3.5% | -1.8% | -3.8% | |
| Operating Margin | 20.0% | 31.5% | 33.6% | 31.4% | 20.5% | 19.2% | 13.9% | 12.8% | 16.6% | 38.4% | 16.9% | 21.5% | 14.9% |
| — | +63.5% | +142.1% | +146.3% | +23.7% | -49.9% | -18.2% | -40.5% | +11.6% | +105.4% | -23.8% | -6.4% | -20.9% | |
| Net Margin | -18.5% | 18.0% | 10.7% | 21.9% | 0.6% | 10.2% | 13.8% | -100.4% | 15.4% | 17.6% | 18.5% | 20.0% | 17.7% |
| — | +76.8% | -22.5% | +121.8% | -96.2% | -42.1% | -25.4% | -603.1% | -13.4% | +22.8% | +54.5% | +81.9% | -10.4% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.0% | 12.2% | 7.5% | 14.5% | 0.4% | 7.1% | 10.0% | -51.7% | 6.0% | 6.3% | 6.5% | 7.2% | 6.3% |
| — | +72.6% | -25.0% | +128.1% | -92.9% | +12.0% | +54.1% | -820.7% | -5.0% | +28.5% | +46.8% | +90.1% | -2.2% | |
| ROA | -9.5% | 2.3% | 1.4% | 2.7% | 0.1% | 1.3% | 1.7% | -12.3% | 1.9% | 2.1% | 2.2% | 2.4% | 2.1% |
| — | +78.7% | -19.3% | +121.6% | -95.9% | -38.4% | -21.4% | -618.2% | -8.8% | +29.0% | +58.0% | +96.7% | -3.7% | |
| ROIC | 12.4% | 5.3% | 5.4% | 4.6% | 3.2% | 2.7% | 2.0% | 1.8% | 2.4% | 5.1% | 2.3% | 2.9% | 2.0% |
| — | +92.2% | +177.3% | +150.9% | +35.6% | -46.5% | -14.1% | -37.3% | +19.2% | +110.8% | -25.1% | -3.1% | -19.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Bristol-Myers Squibb Company Ce's Debt/EBITDA ratio is 10.5x, up from 9.9x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.12 | 2.74 | 2.91 | 2.94 | 3.12 | 2.99 | 3.16 | 3.47 | 1.41 | 1.35 | 1.22 | 1.23 | 1.31 |
| — | -8.2% | -8.0% | -15.4% | +122.2% | +121.2% | +158.6% | +181.0% | +7.5% | +10.3% | -7.2% | -15.0% | +3.3% | |
| Debt / EBITDA | 2.66 | 10.48 | 9.90 | 11.26 | 11.64 | 10.53 | 12.60 | 14.19 | 9.49 | 5.89 | 9.04 | 8.10 | 9.66 |
| — | -0.5% | -21.4% | -20.6% | +22.6% | +78.8% | +39.3% | +75.2% | -1.7% | -31.2% | +9.8% | -7.5% | +2.3% | |
| Current Ratio | 1.25 | 1.27 | 1.21 | 1.28 | 1.25 | 1.24 | 1.16 | 1.11 | 1.43 | 1.18 | 1.39 | 1.42 | 1.25 |
| — | +2.1% | +4.4% | +15.2% | -12.2% | +5.3% | -17.0% | -21.8% | +14.5% | -16.8% | -3.5% | +7.5% | -18.1% | |
| Quick Ratio | 1.15 | 1.17 | 1.11 | 1.17 | 1.15 | 1.09 | 1.02 | 0.99 | 1.31 | 1.07 | 1.28 | 1.28 | 1.14 |
| — | +6.9% | +8.2% | +17.4% | -12.4% | +1.8% | -19.8% | -22.5% | +14.8% | -17.8% | -4.8% | +4.5% | -20.1% | |
| Interest Coverage | 4.96 | 8.01 | 8.49 | 7.13 | 5.10 | 4.53 | 3.25 | 3.56 | 6.02 | 15.05 | 6.74 | 8.44 | 5.76 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonBristol-Myers Squibb Company Ce's current P/E is -0.0x. The average P/E over the last 4 quarters is 0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bristol-Myers Squibb Company Ce's current operating margin is 20.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bristol-Myers Squibb Company Ce's business trajectory between earnings reports.